BioSpace News Archive

Apyx Medical Corporation (NASDAQ:APYX) (the “Company”), a maker of medical devices and supplies and the developer of Helium Plasma Technology, marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market, announced today that management will participate in the following upcoming investor conferences

Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing novel vaccines, today announced that Ryan Spencer, Chief Executive Officer, will participate in a virtual fireside chat at the H.C. Wainwright Virtual 22nd Annual Global Investment Conference

Cardinal Health (NYSE: CAH) announced today that its board of directors has elected Sheri Edison as an independent director, effective September 1.

Helix BioPharma Corp. (TSX:HBP) (“Helix” or the “Company”), a clinical-stage biopharmaceutical company developing unique therapies in the field of immuno-oncology based on its proprietary technological platform DOS47, today announced an update on the progress regarding the non-binding term sheet the Company received and previous announced on June 26, 2020

Relay Medical Corp. (“Relay” or the “Company”) (CSE: RELA, OTC: RYMDF, Frankfurt: EIY2), and Fio Corporation (“Fio”) announce the signing of U.S. and French distribution partners for the Fionet Mobile COVID-19 testing and tracking platform.

MCRA, LLC, a leading medical device and biologics advisory firm and clinical research organization (CRO) is pleased to announce the expansion of its digital health and cybersecurity franchise.

Astex Pharmaceuticals, Inc., a wholly owned subsidiary of Otsuka Pharmaceutical Co., Ltd., based in Tokyo, Japan, announces that the US Food & Drug Administration (FDA) has granted orphan drug designation for the company’s novel, orally administered non-peptidomimetic antagonist of the cellular and X-linked inhibitors of apoptosis proteins (cIAP1/2 and XIAP)

Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today provided an update on its development program for tradipitant

parta Group (TSXV:SAY) (the “Corporation” the “Company”, “Sparta Group”, “Sparta Capital” or “Sparta”) announces it has released its financial results for the nine months ended June 30, 2020.

Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that the subscription period of its previously announced rights offering expired at 5:00 p.m., New York City time